Fatty Liver Disease Affects 1 Billion People Globally – Can Three New Drug Classes Reverse It?

1 billion people worldwide have fatty liver disease. Can three new drug classes reverse it?

This article is for health science popularization and informational purposes only. It does not constitute medical advice. Please consult a qualified healthcare professional for any health concerns.

Many people have seen the words "fatty liver" on their physical examination reports, and many have not taken it seriously – "It doesn't hurt or itch, just eat less oil." But you may not know: the progression from simple fatty liver to metabolic dysfunction-associated steatohepatitis (MASH), and then to liver fibrosis, cirrhosis, and even liver cancer, can take only 5 to 10 years. Globally, 1 in 4 adults has fatty liver disease. Between 2024 and 2025, the New England Journal of Medicine (NEJM) published three large Phase III clinical trials consecutively, demonstrating for the first time at the histological level that tirzepatide, semaglutide, and resmetirom can reverse moderate-to-severe steatohepatitis and reduce liver fibrosis. What does this mean? Who needs to pay attention? Which indicators should be monitored during routine check-ups?

I. The Underestimated "Silent Epidemic"

Fatty liver disease (medically known as MASLD, Metabolic Dysfunction-Associated Steatotic Liver Disease) is not exclusive to overweight individuals. Lean people and non-drinkers can also be affected – insulin resistance, abdominal obesity, hyperlipidemia, and type 2 diabetes are all underlying drivers.

More critically, fatty liver disease is virtually asymptomatic in its early stages. By the time symptoms like fatigue, dull pain in the right upper abdomen, or jaundice appear, significant inflammation or fibrosis is often already present. Remember this: Fatty liver is not a "sub-health" condition; it is a chronic disease that requires management.

II. From "No Available Drugs" to "Three Pillars": What Did the NEJM Trilogy Say?

For a long time, the standard treatment for MASH was only six words: weight loss, exercise, diet. No drug had received formal FDA approval – until 2024.

1. Resmetirom: The First Approved MASH Drug

In March 2024, the FDA granted accelerated approval to Resmetirom (brand name Rezdiffra) for adults with MASH and moderate-to-severe liver fibrosis, making it the world's first formally approved MASH treatment. Key data from the MAESTRO-NASH Phase III trial (NEJM 2024): After 52 weeks of treatment, approximately 26%-30% of patients in the 80mg/day group achieved MASH resolution without worsening of fibrosis, compared to only about 10% in the placebo group. In the 100mg/day group, the proportion achieving at least a 1-stage improvement in fibrosis without MASH worsening was approximately 24%-26%, versus about 14% in the placebo group. Mechanism of action: A selective thyroid hormone receptor-beta (THR-β) agonist that acts directly on the liver, promoting fat metabolism and reducing liver inflammation and fibrosis.

2. Tirzepatide: A Liver Surprise from the GLP-1/GIP Dual Target

In July 2024, the SYNERGY-NASH trial was published in NEJM: 190 patients with biopsy-confirmed MASH and F2/F3 fibrosis were randomized to receive tirzepatide (5/10/15mg) or placebo for 52 weeks. MASH resolution rate (without fibrosis worsening): placebo 10%, tirzepatide 5mg group 44%, 10mg group 56%, and 15mg group up to 63%. Fibrosis improvement by at least 1 stage (without MASH worsening): placebo 30%, tirzepatide dose groups approximately 51%-55%. Weight change: average weight loss of approximately 15% in the 15mg group, compared to about 1% in the placebo group. Tirzepatide is a GIP/GLP-1 receptor dual agonist, originally used for type 2 diabetes and obesity. The study showed that weight loss itself significantly improves liver fat deposition and inflammation.

3. Semaglutide: The ESSENCE Breakthrough at 2.4mg Dose

In June 2025, the highly anticipated ESSENCE Phase III trial was published in NEJM: 1197 patients with biopsy-confirmed MASH and F2/F3 fibrosis were randomized 2:1 to receive semaglutide 2.4mg once weekly or placebo, with a total treatment duration of 240 weeks (~4.6 years). The 72-week interim analysis showed: MASH resolution rate (without fibrosis worsening): 62.9% in the semaglutide group vs. 34.3% in the placebo group (difference of 28.7 percentage points, P<0.001). Fibrosis improvement by at least 1 stage (without MASH worsening): 36.8% in the semaglutide group vs. 22.4% in the placebo group (difference of 14.4 percentage points, P<0.001). Weight change: average -10.5% in the semaglutide group vs. -2.0% in the placebo group. Final 240-week data will be reported later. This is the largest and longest-duration MASH drug trial to date.

Comparison of the Three Drug Classes

Note: All of the above are prescription drugs with specific indications and contraindications. Whether they are suitable and which regimen to use must be determined by a gastroenterologist, hepatologist, or endocrinologist based on liver biopsy or non-invasive assessment results. Do not self-medicate.

III. Why Are GLP-1 Drugs Also Effective for the Liver?

You might ask: Aren't semaglutide and tirzepatide glucose-lowering/weight-loss drugs? How can they also improve liver inflammation? The answer lies in metabolic linkage: - Weight loss directly reduces liver fat: A 5%-10% weight loss can significantly reduce triglyceride content in the liver; with a loss of over 10%, liver inflammation and fibrosis begin to reverse in some patients. - Improves insulin resistance: GLP-1 receptor agonists enhance insulin sensitivity, reducing hepatic de novo lipogenesis and free fatty acid influx at the source. - Direct anti-inflammatory and anti-fibrotic effects: Basic research suggests GLP-1 receptors are expressed on hepatocytes and hepatic stellate cells, and their activation may directly inhibit inflammatory signaling and fibrotic pathways. - Multiple cardiometabolic benefits: Simultaneously improves blood pressure, lipids, and glucose, reducing cardiovascular event risk – particularly important for MASH patients, whose primary cause of death is often cardiovascular disease rather than liver failure.

A 2025 systematic review and network meta-analysis (Metabolism 2025) also confirmed that GLP-1 receptor agonists and co-agonists are highly effective in improving body composition (reducing fat mass, relatively preserving lean mass), further supporting their comprehensive value in metabolic diseases.

IV. 5 Things the General Public Needs to Know

1. Add These Two Tests to Your Check-up - Liver function (ALT/AST): Mildly elevated ALT (alanine aminotransferase) is the most common signal of fatty liver, but approximately 30%-40% of fatty liver patients have completely normal ALT, so transaminases alone cannot be relied upon. - Abdominal ultrasound / Liver elastography (FibroScan): Ultrasound can detect moderate-to-severe fatty liver; FibroScan uses transient elastography to assess the degree of liver fibrosis. It is non-invasive, rapid, and suitable for screening high-risk populations.

2. These Are High-Risk Groups – Proactive Screening Recommended - BMI ≥ 24 (overweight) or waist circumference ≥ 90cm in men, ≥ 85cm in women - Patients with type 2 diabetes - Patients with hypertension, hyperlipidemia, hyperuricemia/gout - Long-term alcohol users or those with a family history of metabolic syndrome - Unexplained mild elevation of ALT/AST

3. Lifestyle Intervention Remains the Cornerstone Even with new drugs, achieving 7%-10% weight loss remains the first-line recommendation for MASH management: - At least 150 minutes of moderate-intensity aerobic exercise per week (brisk walking, cycling, swimming) - 2-3 sessions of resistance training per week (helps preserve muscle mass, especially important during weight loss) - Reduce intake of refined sugars (especially sugary drinks) and saturated fats - Limit alcohol consumption; preferably abstain entirely

4. Drugs Are Not "Take-If-You-Want" Currently, all MASH drugs are prescription medications requiring: - Confirmation of MASH with F2 or higher fibrosis by a physician (usually requiring liver biopsy or non-invasive assessments like FibroScan) - Exclusion of other liver disease causes (viral hepatitis, autoimmune liver disease, etc.) - Use under physician monitoring with regular follow-up of liver function and imaging

5. Don't Wait for Symptoms to Act MASH is called the "silent killer" – before decompensated cirrhosis, there may be no specific symptoms at all. By the time ascites or gastrointestinal bleeding appears, the optimal intervention window has already been missed.

V. Final Thoughts

From "no available drugs" in 2023 to "three pillars" by 2026, the changes in the MASH treatment landscape represent one of the most exciting advances in metabolic medicine in recent years. However, breakthroughs in medication do not mean you can relax lifestyle management – drugs are the lever, lifestyle is the fulcrum; only their combination can truly reverse the disease trajectory.

If you or a family member have abdominal obesity, diabetes, or have been found to have fatty liver on a check-up, proactively discuss liver elastography with your doctor at your next physical exam. Early detection, early assessment, and early intervention – fatty liver disease can be reversed. We recommend saving this article and forwarding it to family and friends whose check-ups have revealed "fatty liver." Understanding is the first step toward change.

References

1. Sanyal AJ, Newsome PN, Kliers I, et al. Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis. N Engl J Med. 2025;392(21):2089-2099. PMID:40305708
2. Loomba R, Hartman ML, Lawitz EJ, et al. Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis. N Engl J Med. 2024;391(4):299-310. PMID:38856224
3. Harrison SA, Bedossa P, Guy CD, et al. A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis (MAESTRO-NASH). N Engl J Med. 2024;390(6):497-509. PMID:38324483
4. Le MH, Yeo YH, Li X, et al. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology. 2023;77(4):1323-1335. PMID:36626630
5. Devarbhavi H, Asrani SK, Arab JP, et al. Global burden of liver disease: 2023 update. J Hepatol. 2023;79(2):536-551. PMID:36990226
6. Wilding JPH, Pras-Raves M, van Golen L, et al. Effect of glucagon-like peptide-1 receptor agonists and co-agonists on body composition: Systematic review and network meta-analysis. Metabolism. 2025;164:156123. PMID:39719170

Disclaimer: This article is based on published peer-reviewed research and public medical literature. It is intended solely for health science popularization and informational purposes and does not constitute any medical advice, medication guidance, or prescription recommendation. The drugs mentioned are prescription medications. Please consult qualified healthcare professionals for specific diagnosis and treatment plans.

Conflict of Interest Statement: This article was independently written by Sun Healthcare (Beijing) Medical Technology Co., Ltd. It received no funding or influence from any pharmaceutical company. All data cited are from publicly available academic literature.

© 2026 Sun Healthcare (Beijing) Medical Technology Co., Ltd.